ClearTract
Commercial- Indications
- Urinary catheter infections
Company intelligence / Profile preview
Silq Technologies has developed a patented zwitterion-based permanent surface treatment that resists organic material adhesion, reducing infection and thrombosis risks in implantable medical devices. Their lead product, the ClearTract® Foley catheter, has received FDA clearance and early commercial rollout. Preliminary results from two randomized clinical trials show highly favorable outcomes; final data are expected soon. The company collaborates with major device manufacturers to expand its technology across various implantable products.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Silq Technologies.